First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 2, 2023 /PRNewswire/ — Cellenkos® Inc., a clinical stage biotechnology company focused on developing…